(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 11 2023
Historique:
revised: 12 04 2023
received: 05 12 2022
accepted: 09 05 2023
medline: 8 9 2023
pubmed: 5 7 2023
entrez: 5 7 2023
Statut: ppublish

Résumé

Fatigue is common in breast-cancer survivors. Our study assessed fatigue longitudinally in breast cancer patients receiving adjuvant radiotherapy (RT) and aimed to identify risk factors associated with long-term fatigue and underlying fatigue trajectories. Fatigue was measured in a prospective multicenter cohort (REQUITE) using the Multidimensional Fatigue Inventory (MFI-20) and analyzed using mixed models. Multivariable logistic models identified factors associated with fatigue dimensions at 2 years post-RT and latent class growth analysis identified individual fatigue trajectories. A total of 1443, 1302, 1203 and 1098 patients completed the MFI-20 at baseline, end of RT, after 1 and 2 years. Overall, levels of fatigue significantly increased from baseline to end of RT for all fatigue dimensions (P < .05) and returned to baseline levels after 2 years. A quarter of patients were assigned to latent trajectory high (23.7%) and moderate (24.8%) fatigue classes, while 46.3% and 5.2% to the low and decreasing fatigue classes, respectively. Factors associated with multiple fatigue dimensions at 2 years include age, BMI, global health status, insomnia, pain, dyspnea and depression. Fatigue present at baseline was consistently associated with all five MFI-20 fatigue dimensions (OR

Identifiants

pubmed: 37403702
doi: 10.1002/ijc.34640
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1579-1591

Subventions

Organisme : Cancer Research UK
ID : C147/A25254
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1094/A18504
Pays : United Kingdom
Organisme : Department of Health
ID : CL 2017-11-002
Pays : United Kingdom
Organisme : Department of Health
ID : DRF 2014-07-079
Pays : United Kingdom

Informations de copyright

© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol. 2014;32:1840-1850.
Hickok JT, Roscoe JA, Morrow GR, Mustian K, Okunieff P, Bole CW. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer. 2005;104:1772-1778.
de Jong N, Candel MJJM, Schouten HC, Huijer Abu-Saad H, Courtens AM. Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol. 2004;15:896-905.
Servaes P, Gielissen MFM, Verhagen S, Bleijenberg G. The course of severe fatigue in disease-free breast cancer patients: a longitudinal study. Psychooncology. 2007;16:787-795.
Abrahams HJG, Gielissen MFM, Schmits IC, Verhagen CAHHVM, Rovers MM, Knoop H. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors. Ann Oncol. 2016;27:965-974.
Schmidt ME, Hermann S, Arndt V, Steindorf K. Prevalence and severity of long-term physical, emotional, and cognitive fatigue across 15 different cancer entities. Cancer Med. 2020;9:8053-8061.
Noal S, Levy C, Hardouin A, et al. One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer. Int J Radiat Oncol Biol Phys. 2011;81:795-803.
Battisti NML, Hatton MQ, Reed MWR, et al. Observational cohort study in older women with early breast cancer: use of radiation therapy and impact on health-related quality of life and mortality. Radiother Oncol. 2021;161:166-176.
Jacobs DHM, Charaghvandi RK, Horeweg N, et al. Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens. Breast Cancer Res Treat. 2021;189:387-398.
Geinitz H, Zimmermann FB, Thamm R, Keller M, Busch R, Molls M. Fatigue in patients with adjuvant radiation therapy for breast cancer: long-term follow-up. J Cancer Res Clin Oncol. 2004;130:327-333.
Hauth F, De-Colle C, Weidner N, et al. Quality of life and fatigue before and after radiotherapy in breast cancer patients. Strahlenther Onkol. 2021;197:281-287.
Ruiz-Casado A, Álvarez-Bustos A, de Pedro CG, Méndez-Otero M, Romero-Elías M. Cancer-related fatigue in breast cancer survivors: a review. Clin Breast Cancer. 2021;21:10-25.
Schmidt ME, Wiskemann J, Schneeweiss A, Potthoff K, Ulrich CM, Steindorf K. Determinants of physical, affective, and cognitive fatigue during breast cancer therapy and 12 months follow-up. Int J Cancer. 2018;142:1148-1157.
Reinertsen KV, Cvancarova M, Loge JH, Edvardsen H, Wist E, Fosså SD. Predictors and course of chronic fatigue in long-term breast cancer survivors. J Cancer Surviv. 2010;4:405-414.
Di Meglio A, Havas J, Soldato D, et al. Development and validation of a predictive model of severe fatigue after breast cancer diagnosis: toward a personalized framework in survivorship care. J Clin Oncol. 2022;40:1111-1123.
Person H, Guillemin F, Conroy T, Velten M, Rotonda C. Factors of the evolution of fatigue dimensions in patients with breast cancer during the 2 years after surgery. Int J Cancer. 2020;146:1827-1835.
Bower JE, Wiley J, Petersen L, Irwin MR, Cole SW, Ganz PA. Fatigue after breast cancer treatment: biobehavioral predictors of fatigue trajectories. Health Psychol. 2018;37:1025-1034.
Vaz-Luis I, Di Meglio A, Havas J, et al. Long-term longitudinal patterns of patient-reported fatigue after breast cancer: a group-based trajectory analysis. J Clin Oncol. 2022;40:2148-2162. doi:10.1200/jco.21.01958
Bower JE, Ganz PA, Irwin M, et al. Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancer. Cancer. 2021;127:1334-1344.
Bean HR, Diggens J, Ftanou M, Weihs KL, Stanton AL, Wiley JF. Insomnia and fatigue symptom trajectories in breast cancer: a longitudinal cohort study. Behav Sleep Med. 2021;19:814-827.
Seibold P, Webb A, Aguado-Barrera ME, et al. REQUITE: a prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiother Oncol. 2019;138:59-67.
Smets EM, Garssen B, Bonke B, et al. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39:315-325.
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and Treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14:2756-2768.
Schwarz R, Krauss O, Hinz A. Fatigue in the general population. Onkologie. 2003;26:140-144.
Kuhnt S, Ernst J, Singer S, et al. Fatigue in cancer survivors - prevalence and correlates. Onkologie. 2009;32:312-317.
Maass SWMC, Brandenbarg D, Boerman LM, Verhaak PFM, De Bock GH, Berendsen AJ. Fatigue among long-term breast cancer survivors: a controlled cross-sectional study. Cancers (Basel). 2021;13:1-11.
Purcell A, Fleming J, Bennett S, Burmeister B, Haines T. Determining the minimal clinically important difference criteria for the multidimensional fatigue inventory in a radiotherapy population. Support Care Cancer. 2010;18:307-315.
Herle M, Micali N, Abdulkadir M, et al. Identifying typical trajectories in longitudinal data: modelling strategies and interpretations. Eur J Epidemiol. 2020;35:205-222.
Ram N, Grimm KJK. Growth mixture modeling: a method for identifying differences in longitudinal change among unobserved groups. Int J Behav Dev. 2009;33:565-576.
Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models using latent classes and latent processes: the R package lcmm. J Stat Softw. 2017;78(2):1-56.
Biering K, Frydenberg M, Pappot H, Hjollund NH. The long-term course of fatigue following breast cancer diagnosis. J Patient-Rep Outcomes. 2020;4:4.
Donovan KA, Jacobsen PB, Andrykowski MA, et al. Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. J Pain Symptom Manage. 2004;28:373-380.
Jacobsen PB, Donovan KA, Weitzner MA. Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsychiatry. 2003;8:229-240.
Bower JE. Cancer-related fatigue-mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11:597-609.
Bower JE, Ganz PA, Irwin MR, et al. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism. J Clin Oncol. 2011;29:3517-3522.
Xiao C, Miller AH, Felger J, Mister D, Liu T, Torres MA. Depressive symptoms and inflammation are independent risk factors of fatigue in breast cancer survivors. Psychol Med. 2017;47:1733-1743.
Ho SY, Rohan KJ, Parent J, Tager FA, McKinley PS. A longitudinal study of depression, fatigue, and sleep disturbances as a symptom cluster in women with breast cancer. J Pain Symptom Manage. 2015;49:707-715.
Trudel-Fitzgerald C, Savard J, Ivers H. Which symptoms come first? Exploration of temporal relationships between cancer-related symptoms over an 18-month period. Ann Behav Med. 2013;45:329-337.
Bødtcher H, Bidstrup PE, Andersen I, et al. Fatigue trajectories during the first 8 months after breast cancer diagnosis. Qual Life Res. 2015;24:2671-2679.

Auteurs

Juan C Rosas (JC)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians University, Munich, Germany.

Miguel E Aguado-Barrera (ME)

Instituto de Investigación Sanitaria de Santiago de Compostela, Fundación Pública Galega de Medicina Xenómica (FPGMX), Santiago de Compostela, Spain.

David Azria (D)

University of Montpellier, INSERM U1194 IRCM, Institut du Cancer Montpellier (ICM), Montpellier, France.

Erik Briers (E)

Patient advocate, Hasselt, Belgium.

Rebecca Elliott (R)

University of Manchester, Manchester, UK.

Marie-Pierre Farcy-Jacquet (MP)

Federation Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut du Cancer Du Gard (ICG), CHU Carémeau, Nîmes, France.

Alexandra Giraldo (A)

Radiation Oncology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Sara Gutiérrez-Enríquez (S)

Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Tiziana Rancati (T)

Istituto Nazionale dei Tumori, Data Science Unit, Milan, Italy.

Tim Rattay (T)

University of Leicester, Leicester, UK.

Victoria Reyes (V)

Radiation Oncology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Barry Rosenstein (B)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Dirk De Ruysscher (D)

Maastro Clinic, Maastricht, The Netherlands.
KU Leuven, Leuven, Belgium.

Elena Sperk (E)

Universitätsmedizin Mannheim, Mannheim Cancer Center, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Hilary Stobart (H)

Independent Cancer Patients' Voice, London, UK.

Christopher Talbot (C)

University of Leicester, Leicester, UK.

Ana Vega (A)

Instituto de Investigación Sanitaria de Santiago de Compostela, Fundación Pública Galega de Medicina Xenómica (FPGMX), Santiago de Compostela, Spain.
Biomedical Network on Rare Diseases (CIBERER), Seville, Spain.

Begoña Taboada-Valladares (B)

Instituto de Investigación Sanitaria de Santiago de Compostela, Fundación Pública Galega de Medicina Xenómica (FPGMX), Santiago de Compostela, Spain.
Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.

Liv Veldeman (L)

Ghent University Hospital, Ghent, Belgium.
Ghent University, Ghent, Belgium.

Tim Ward (T)

NCRI CTRad Consumer, London, UK.

Adam Webb (A)

University of Leicester, Leicester, UK.

Catharine West (C)

University of Manchester, Manchester, UK.

Jenny Chang-Claude (J)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Petra Seibold (P)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH